Direct comparison
Retatrutid vs Survodutid
Class
GLP-1 analog
GLP-1 analog
Mechanism
Retatrutide is a triple agonist at GIP, GLP-1 and glucagon receptors (GGG agonist).
Survodutide is a dual agonist at glucagon and GLP-1 receptors.
Studied effects
Metabolism
Metabolism
Evidence level
early clinical studies
early clinical studies
Legal status (DE)
not approved
not approved
WADA-listed
No
No
Half-life
~6 days
~6–7 days (once weekly)
Studies cited
2
2
Sourcing & partnersAd
europeptidesPEPTICA
europeptides
Visit partner →unyxpeptides
unyxpeptides
Visit partner →clearpeptidesPeptica
clearpeptides
Visit partner →Partner / affiliate links — Peptica may earn a commission. No endorsement; not medical advice. Peptica sells no substances.
Related comparisons
Important notice
This site is intended solely for factual, scientifically oriented information about peptides. It does not constitute medical advice, does not replace a consultation with a doctor and contains no recommendations for use in humans. Peptica sells no substances and names no sources for unapproved substances.